Kestra Medical Technologies, Ltd. KMTS NASDAQ

NASDAQ Global Select • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

49/100

2/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Kestra Medical Technologies, Ltd. (KMTS) generated $-77.61M in operating cash flow for fiscal year 2025. After capital expenditures of $23.59M, free cash flow was $-101.2M.

Free cash flow margin was -169.2% of revenue. Cash conversion ratio was 0.68x, suggesting some earnings are non-cash.

The company returned $1.65M in dividends to shareholders during the period.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (55/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was 0.68x suggests some earnings are non-cash items

Overall SharesGrow Score: 49/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

49/100

SG Score

View full scorecard →

✓

VALUE

71/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

85/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

55/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Kestra Medical Technologies, Ltd. Cash Flow History

Metric	TTM	FY2025	FY2023	FY2022	FY2020
Operating Cash Flow	$-86.68M	$-77.61M	$-72.24M	$-69.64M	$-29.9M
Capital Expenditure	$-33.27M	$-23.59M	$-12.51M	$-15.46M	$-336K
Free Cash Flow	$-119.95M	$-101.2M	$-84.75M	$-85.1M	$-30.23M